Staging of Myeloma. A Preliminary Study of Staging Factors and Treatment in Different Stages

  • E. Ösby
  • B. Carlmark
  • P. Reizenstein
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 65)


Almost all tumors originating in the lymphatic cell system, except myelomas, are staged. The intensity and type of treatment is usually adapted to the stage of the disease. In more malignant or advanced stages, fairly intense combination chemotherapy is often used. In myelomas, treatment has often been less intense. Often a single cytostatic is used. Since myelomas are not usually staged, this is true even for advanced stages and malignant forms. However, staging procedures for myeloma have been proposed [4, 5]. For such a procedure to be clinically relevant, prognostic differences between the different stages have to be established. The present purpose was to study whether initial clinical parameters can be found which are correlated to the prognosis in myeloma. In addition, a differentiated program for treatment of the different stages is proposed, and some preliminary treatment results are reported.


Creatinine Sedimentation Electrophoresis CaCl Melphalan 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alexanian, R., Haut, A., Khan, A. U., Lane, M., McKelvey, E. M., Migliore, P. J., Stickey, W. J., and Wilson, H. E.: Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regiments. JAMA 208, 1680–1685 (1969)PubMedCrossRefGoogle Scholar
  2. 2.
    Alexanian, R., Balcerzah, S., Bonnet, J. D., Gehan, E. A., Haut, A., Hewlett, J. S., and Monto, R. W.: Prognostic factors in multiple myeloma. Cancer 36, 1192–1201 (1975)PubMedCrossRefGoogle Scholar
  3. 3.
    Arman, E., and Reizenstein, P.: Hand radioactivity after intravenous injection of 47Ca. Effect of age and femoral neck fracture. Geriatrics 26–165 (1971)Google Scholar
  4. 4.
    Durie, B. G. M., and Salmon, S. E.: A clinical staging system for multiple myeloma. Cancer 36, 842- 854 (1975)PubMedCrossRefGoogle Scholar
  5. 5.
    Durie, B. G. M., and Salmon, S. E.: Cellular kinetics, staging, and immunoglobulin synthesis in multiple myeloma. Annu. Rev. Med. 26, 283–288 (1975)PubMedCrossRefGoogle Scholar
  6. 6.
    Feinleib, M., and Mac Matron, B.: Duration of survival in multiple myeloma. J. Natl. Cancer Inst. 24, 1259–1269 (1960)PubMedGoogle Scholar
  7. 7.
    Galton, D. A. G., and Peto, R.: A progress report on the Medical Research Council’s therapeutic trial in myelomatosis. Br. J. Haematol. 15, 319–320 (1968)PubMedCrossRefGoogle Scholar
  8. 8.
    Hobbs, J. R.: Growth rates and responses to treatment in human myelomatosis. Br. J. Haematol. 16, 607–617 (1969)PubMedCrossRefGoogle Scholar
  9. 9.
    Hobbs, J. R.: Monitoring myelomatosis. Arch. Intern. Med. 135, 125–130 (1975)PubMedCrossRefGoogle Scholar
  10. 10.
    Innes, J., and Newall, J.: Myelomatosis. Lancet I, 239–245 (1961)CrossRefGoogle Scholar
  11. 11.
    Salmon, S. E.: Expansion of the growth fraction in multiple myeloma with alkylating agents. Blood 45, 119–129 (1975)PubMedGoogle Scholar
  12. 12.
    Sjöberg, H. E.: Retention of 47calcium administered orally in patients with primary hyperparathyroidism. Horm. Metab. Res. 2, 32–34 (1970)PubMedCrossRefGoogle Scholar
  13. 13.
    Sjöberg, H. E., Reizenstein, P., and Arman, E.: Retention of orally administered 47Ca in man measured in a whole-body counter. Scand. J. Clin. Lab. Invest. 26, 67–71 (1970)PubMedCrossRefGoogle Scholar
  14. 14.
    Waldenström, J.: Diagnosis and treatment of multiple myeloma. New York, London, Grune and Stratton (1970)Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1978

Authors and Affiliations

  • E. Ösby
  • B. Carlmark
  • P. Reizenstein

There are no affiliations available

Personalised recommendations